On Sept 23, 2021, we are excited to have these deal makers as the speakers at this special panel to share their experiences, insights, and forecast of global biopharma collaboration. These distinguished speakers are:

PANEL DISCUSSION: “CHINA FOR GLOBAL: OUT-LICENSING OPPORTUNITIES, CHALLENGES, AND PERSPECTIVES”

MODERATOR: Echo Hindle-Yang, MSQ Ventures, President and CEO

PANELISTS:

• Joan (Huaqiong) Shen, I-Mab Biopharma, CEO
• Sridhar Gopal, AbbVie, Head of International Business Development
• Natasha Hernday, Seagen, Executive Vice President of Corporate Development and Alliance Management
• Michael Fleming, Coherus BioSciences, Chief Strategy Officer
• Sean Zhang, MD, FCP, InnoCare Pharma 诺诚健华(HKEX：09969), CMO

PANEL DISCUSSION: “CROSS-BORDER COLLABORATION OPPORTUNITIES: UNMET MEDICAL NEEDS AND EMERGING TECHNOLOGIES IN CHINA”

As we see the surge of China cross-border collaborations in recent years, one key question to ask is what are China’s true unmet medical needs? Apparently, oncology has gained tremendous traction, and expects to keep its dominant role, but are there any other opportunities being overlooked?

We are excited to have a group of opinion leaders, each of whom has unique experience and expertise in regulatory affairs, VC/PE, and/or entrepreneurship will share their insights from a range of perspectives.

MODERATOR: Dr. Jingzhen (Ginger) Ding, MSQ Ventures, Managing Director

PANELISTS

• Dr. Jun Bao, IMPACT Therapeutics 英派药业, President and CEO
• Dr. Tom Du, Evergreen Therapeutics, Inc., Co-founder and Chairman
• Dr. Jack Wu, Antengene, Head of Global BD Search & Evaluation
• Dr. S. Frank Yan, 3E Bioventures Capital, Partner
• Dr. Chunlin Adam Zhao, AnLong Bio, Founder and CEO